# Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)

> **NCT04363827** · PHASE2 · TERMINATED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 155 (actual)

## Conditions studied

- COVID19
- Hydroxychloroquine
- Prophylaxis
- Treatment
- SARS-CoV-2

## Interventions

- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT04363827
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-14
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 155 (ACTUAL)
- **Why stopped:** Difficulties in recruiting subjects were observed soon after the study was initiated. This difficulty was attributed to the decreased incidence of infections which occurred in the period following the first lock down.
- **Last updated:** 2025-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04363827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04363827, "Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04363827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*